• Oct 26, 2026

  $140.61-3.21%

  Merck shares fell 3.21% while comparable pharmaceutical companies moved +0.11% on average, with 4 of 6 rising, so the decline was not shared by the group [3]. Seeking Alpha carried a headline reporting that Merck's sac-TMT significantly cut death risk in endometrial cancer [2]. It also published a transcript of a Merck shareholder/analyst call held that day [1].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Peer group

• Oct 23, 2026

  $145.27-1.34%

  Merck fell 1.34% on a day when comparable pharmaceutical companies fell 0.98% on average, with 4 of 6 lower [3]. Seeking Alpha reported that Merck and Moderna released phase 3 data on October 22, 2026 for their vaccine and Keytruda combination in melanoma patients after surgery [2]. 24/7 Wall St reported that Moderna slid further and that Merck and Pfizer slipped [1].

  • 124/7 Wall St
  • 2Seeking Alpha
  • 3Peer group

• Oct 22, 2026

  $147.24-1.76%

  Merck fell 1.76% while comparable pharmaceutical companies rose 2.16% on average, with all 6 higher [2]. The decline was therefore not shared by the group. Seeking Alpha reported that Moderna shares plunged on leaked cancer vaccine data [1]. Volume was 2.1x the trailing 20-session average, and the session ranged from 144.07 to 154.02 [3].

  • 1Seeking Alpha
  • 2Peer group
  • 3Market data

• Oct 21, 2026

  $149.88+1.07%

  Seeking Alpha reported that the European Commission approved the Keytruda and Padcev combination for bladder cancer [1]. Merck closed up 1.07% that day.

  • 1Seeking Alpha

• Oct 20, 2026

  $148.30+3.25%

  Comparable pharmaceutical companies rose 2.09% on average, with 5 of 6 higher [1]. The share price rise came alongside that move in the group, so it was largely shared rather than specific to this company [1].

  • 1Peer group

• Oct 19, 2026

  $143.63-1.59%

  Merck fell 1.59% while comparable pharmaceutical companies fell 0.67% on average, with 5 of 6 declining [1]. BMY fell 1.54% and ABBV 0.96%, while VRTX rose 0.44% [1]. The decline was larger than the group's average move.

  • 1Peer group

• Oct 16, 2026

  $145.95+0.52%

Closing prices for MRK. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.